2nd Quarter - Amendment

ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$520,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 21, 2014 $480,000 Replaced
2nd Quarter - Amendment Jul 22, 2014 $480,000 Replaced
2nd Quarter - Amendment (this page) Aug 19, 2014 $520,000 Replaced
2nd Quarter - Amendment Jun 10, 2015 $520,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes

LobbyistCovered position, as disclosed
THERESA JOLIVETTE —
JACQUELINE POMFRET KIRBY —
JOHN MYERS —
BELA SASTRY —

Contacted: State, Dept of (DOS); Commerce, Dept of (DOC); SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Patent & Trademark Office (PTO)

Bills named: H.R. 3590 (113th)

Trade (domestic/foreign) TRD

Intellectual property and issues in China and potential impact on US entities

LobbyistCovered position, as disclosed
BRADLEY ALLEN ROSSIN —

Contacted: State, Dept of (DOS); SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO)

Copyright/Patent/Trademark CPT

S 1720 - patent litigation reform Issues related to intellectual property practices in foreign countries and impact on US entities

LobbyistCovered position, as disclosed
THERESA JOLIVETTE —
JACQUELINE POMFRET KIRBY —
BRADLEY ALLEN ROSSIN —
BELA SASTRY —

Contacted: State, Dept of (DOS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); SENATE

Taxation/Internal Revenue Code TAX

HR 4679 Stop Corporate Inversions Act of 2014, S 2360 Stop Corporate Inversions Act of 2014 (in the context of corporate acquisition activity)

LobbyistCovered position, as disclosed
JACQUELINE POMFRET KIRBY —
JOHN MYERS —
BELA SASTRY —

Contacted: U.S. Trade Representative (USTR); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); State, Dept of (DOS); SENATE

Bills named: H.R. 4679 (113th)

Health Issues HCR

Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program Issues related to pediatric medication access and impact of public guidelines on access Issues related to oncology legislation, including medication affordabilityIssues related to 21st Century Cures legislation and role of incentives in advancement of treatments and cures Issues related to FDA and Biomedical Advanced Research Development Authority appropriations (no bill number) Medication adherence related legislation (no bill number)

LobbyistCovered position, as disclosed
MARIA FIRVIDA —
THERESA JOLIVETTE —
JACQUELINE POMFRET KIRBY —
JOHN MYERS —
BELA SASTRY —

Contacted: HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Commerce, Dept of (DOC); SENATE; U.S. Trade Representative (USTR); Patent & Trademark Office (PTO)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.